An investigation into the effect and mechanisms of action of nicotine in inflammatory bowel disease

被引:65
|
作者
Sykes, AP
Brampton, C
Klee, S
Chander, CL
Whelan, C
Parsons, ME
机构
[1] Univ Hertfordshire, Dept Biosci, Hatfield AL10 9AB, Herts, England
[2] Univ Luton, Fac Sci Technol & Design, Dept Biol & Hlth Sci, Luton LU1 3JU, Beds, England
关键词
inflammatory bowel disease; nicotine; TNBS; sulphasalazine; TNF alpha;
D O I
10.1007/s000110050597
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Objective and Design: To determine the effect of nicotine on colonic inflammation in the trinitrobenzenesulphonic acid (TNBS) model of inflammatory bowel disease in comparison with sulphasalazine. Materials: Male Wistar rats were used for the in-vivo and exvivo studies. In-vitro studies were performed using human leukemia peripheral blood monocyte cells (THP-1 cells) grown in continuous culture. Treatment: Rats were given access to either nicotine (5 or 100 mu g/mL) or sulphasalazine (375 mu g/mL) in their drinking water for 10 or 2 days respectively before and 3 days after TNBS administration. THP-1 cells were treated with nicotine (10(-14) to 10(-11) M) for 2h before and after stimulation with 3 mu g/mL lipopolysaccharide (LPS). Methods: Inflammation in the TNBS model was assessed by measuring the tissue myeloperoxidase activity, leukotriene B-4 concentration, inducible nitric oxide protein expression, the ex-vivo production of tumour necrosis factor alpha (TNF alpha), macroscopic damage score, plasma corticosterone levels and by a qualitative histological evolution. The effect of nicotine on TNF alpha production in LPS stimulated THP-1 monocyte cells in-vitro was also determined. Statistical comparisons were made using the Mann-Whitney U-test for the macroscopic damage score and an ANOVA for all other parameters. Results. TNBS treated rats given access to 100 mu g/mL nicotine in their drinking water had a marked reduction in several of the markers of inflammation compared to control TNBS treated rats, but a greater reduction was found at 5 pg/mL, nicotine or 375 mu g/mL sulphasalazine, the latter producing comparable reductions in inflammation to the low dose nicotine. Nicotine also caused a significant reduction in TNF alpha release from THP-1 cells. Conclusions: Nicotine reduced inflammation in the TNBS model of colonic damage confinning the use of nicotine in IBD although the choice of dose requires further investigation. The mechanism of action of nicotine does not involve increased corticosterone levels, but may be a consequence of a reduction in TNF alpha or leukotriene B-4 production.
引用
收藏
页码:311 / 319
页数:9
相关论文
共 50 条
  • [1] An investigation into the effect and mechanisms of action of nicotine in inflammatory bowel disease
    A.P. Sykes
    C. Brampton
    S. Klee
    C.L. Chander
    C. Whelan
    M.E. Parsons
    Inflammation Research, 2000, 49 : 311 - 319
  • [2] Effect of nicotine on inflammatory bowel disease
    Naser, SA
    Ghobrial, G
    Miles, H
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2001, 96 (12): : 3455 - 3457
  • [3] The effect of mesalamine and nicotine in the treatment of inflammatory bowel disease
    Bonapace, CR
    Mays, DA
    ANNALS OF PHARMACOTHERAPY, 1997, 31 (7-8) : 907 - 913
  • [4] Probiotics in inflammatory bowel disease: possible mechanisms of action
    Dotan, I
    Rachmilewitz, D
    CURRENT OPINION IN GASTROENTEROLOGY, 2005, 21 (04) : 426 - 430
  • [5] Mechanisms of action of conventional drugs in inflammatory bowel disease
    Egan, LJ
    Inflammatory Bowel Disease: Translation From Basic Research to Clinical Practice, 2005, 140 : 173 - 179
  • [6] Mechanisms of steroid action and resistance in inflammatory bowel disease
    Kelleher, D.
    McManus, R.
    COLITIS: DIAGNOSIS AND THERAPEUTIC STRATEGIES, 2006, 147 : 87 - +
  • [7] Mechanisms of action of infliximab in inflammatory bowel disease: an anti-inflammatory multitasker
    Danese, S.
    DIGESTIVE AND LIVER DISEASE, 2008, 40 : S225 - S228
  • [8] Therapeutic leukocytapheresis in inflammatory bowel disease: clinical efficacy and mechanisms of action
    Mitsuyama, Keiichi
    Sata, Michio
    CYTOTHERAPY, 2009, 11 (02) : 229 - 237
  • [9] MECHANISMS OF DISEASE Inflammatory Bowel Disease
    Abraham, Clara
    Cho, Judy H.
    NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (21): : 2066 - 2078
  • [10] Novel drug candidate for the treatment of Inflammatory Bowel Disease with unique mechanisms of action
    Lee, J.
    Kim, G.
    Kim, J. C.
    Park, J. H.
    Han, C.
    Kim, M.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : I261 - I261